Locking hemodialysis catheters with cefotaxime instead of gentamicin to avoid potential ototoxicity
To the Editor: McIntyre et al compared gentamicin (5 mg/mL) and heparin-locked, tunneled hemodialysis catheter group with that of catheter-restricted filling of standard heparin (5000 IU/mL) alone; gentamicin-locked group recorded significantly lower catheter-related bloodstream infections catheter-related bloodstream infections (CRBSI) episodes compared with heparin group (0.3/1000 vs. 4/1000 catheter days, P = 0.02) [1] . Dogra et al observed significantly lower incidence of CRBSI (0.03 vs. 0.42 per 100 catheter days, P = 0.003), and considerably higher mean infection-free catheter survival in the gentamicin group (catheter-restricted filling of gentamicin/citrate, 40 mg/mL, and 3.13% citrate) compared with heparin group (282 days vs. 181 days, P = 0.002). However, authors cautioned to establish the safety of 'locked' dose of gentamicin for ototoxicity before the technique was adopted because predialysis plasma gentamicin levels were significantly higher in patients randomized to gentamicin group compared with heparin group (2.8 mg/L vs. <0.2 mg/L, P = 0.008) [2] .
In view of recently reported ototoxicity [3, 4] regardless of reasonably lower amount of aminoglycosides being used for 'locking' catheters, a prospective case-controlled study was carried out at our center using cefotaxime (10 mg/mL) in combination with heparin (5000 U/mL) to examine the lock's efficacy in the prevention of CRBSI [5] . Cefotaxime was chosen because of its broad antimicrobial spectrum and lack of ototoxic potentials. The 'lock' was applied two/three times a week postdialysis. A significant relative-risk reduction in the incidence of HD-tunneled catheter thromboses (1.340-4.701, P = 0.003), CRBSI-incidence (3.086-6.430, P < 0.0001), and CRBSI-related mortality (1.517-5.864, P < 0.001) was 
